4.4 Article

Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy

Journal

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 27, Issue -, Pages 206-216

Publisher

CELL PRESS
DOI: 10.1016/j.omtm.2022.09.014

Keywords

-

Funding

  1. EFSD/Lilly Young Investigator Research Award Programme
  2. Wellcome Trust ISSF Fellowship Support Fund
  3. Diabetes UK RD Lawrence Fellowship [21/0006280]
  4. Diabetes UK [18/0005884]

Ask authors/readers for more resources

This study suggests that gene therapy has the potential to be an effective treatment for congenital generalized lipodystrophy type 2. Using a mouse model, researchers found that systemic adeno-associated virus delivery of the BSCL2 gene could restore white adipose tissue development and improve metabolic health in adult seipin knockout mice. The findings highlight the therapeutic potential of gene therapy for correcting metabolic complications in patients with congenital lipodystrophy.
Congenital generalized lipodystrophy type 2 is a serious multisystem disorder with limited treatment options. It is caused by mutations affecting the BSCL2 gene, which encodes the protein seipin. Patients with congenital generalized lipodystrophy type 2 lack both metabolic and mechanical adipose tissue and develop severe metabolic complications including hepatic steatosis, lipoatrophic diabetes, and cardiovascular disease. Gene therapies are becoming viable treatments, helping to alleviate inherited and acquired human disorders. We aimed to determine whether gene therapy could offer an effective form of medical intervention for lipodystrophy. We examined whether systemic adeno-associated virus delivery of human BSCL2 could reverse metabolic disease in seipin knockout mice, where white adipose tissue is absent. We reveal that adeno-associated virus gene therapy targets adipose progenitor cells in vivo and substantially restores white adipose tissue development in adult seipin knockout mice. This resulted in both rapid and prolonged beneficial effects to metabolic health in this preclinical mouse model of congenital generalized lipodystrophy type 2. Hyperglycemia was normalized within 2 weeks post-treatment together with normalization of severe insulin resistance. We propose that gene therapy offers great potential as a therapeutic strategy to correct multiple metabolic complications in patients with congenital lipodystrophy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available